ReviewCurrent neurology and neuroscience reports2015
Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease.
Review in Current neurology and neuroscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Exploring the relationship between orthostatic hypotension and gait in people with Parkinson's disease.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Article
- Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension.Current neurology and neuroscience reports · 2021Review
- Orthostatic hypotension and health-related quality of life among community-living older people in Korea.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer.Neurology and therapy · 2019Review
- Six-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension.Movement disorders clinical practice · 2019Article
- Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers.BMC neurology · 2018Article
- Genomics of Cardiovascular Measures of Autonomic Tone.Journal of cardiovascular pharmacology · 2018Review
- Superficial siderosis associated with peripheral autonomic failure and tetraventricular hydrocephalus: a case report.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2017Article
- Pathophysiology and Treatment of Orthostatic Hypotension in Parkinsonian Disorders.Current treatment options in neurology · 2016Review
- Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction.Cardiology in reviewReview
- Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease.Movement disorders clinical practiceArticle
- Orthostatic Hypertension and Hypotension and Outcomes in CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.Kidney medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The autonomic nervous system appears to be uniquely susceptible to degeneration in disorders of α-synuclein pathology. Clinically, autonomic dysfunction in these disorders manifests as neurogenic orthostatic hypotension (nOH), a condition that results in substantial morbidity and mortality. nOH results from pathology affecting either the central autonomic pathways or peripheral autonomic nerve fibers. Determining the localization and pathophysiology of nOH is critical in effectively managing this disorder and selecting appropriate treatment options. In this review, we discuss the pathophysiology of nOH with respect to the various α-synuclein-related neurodegenerative conditions. We highlight the associated clinical features, including gait instability, rapid eye movement behavior disorder, and hyposmia. We also review the current pharmacologic treatment options for nOH. Overall, the goals of therapy are to improve symptoms and prevent syncope and falls. Non-pharmacologic interventions should be introduced first, followed by carefully selected pharmacologic therapies. Treatment decisions should be directed by an understanding of the underlying pathophysiology, as well as the comorbidities and potential contributing factors present in each individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.